SYNACT — SynAct Pharma AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK236.72m
- SEK174.97m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3.56 | 14.5 | 24 | 108 | 62.4 |
Net Total Receivables | 4.62 | 6.46 | 10.7 | 14.7 | 12.4 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 8.45 | 21.3 | 34.9 | 140 | 75.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 0 | 3.18 | 2.1 | 0.66 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 23.8 | 21.6 | 38.4 | 143 | 228 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10.3 | 5.72 | 15.4 | 15 | 24.9 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.3 | 5.72 | 17.5 | 16.1 | 51.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 13.5 | 15.9 | 20.9 | 127 | 176 |
Total Liabilities & Shareholders' Equity | 23.8 | 21.6 | 38.4 | 143 | 228 |
Total Common Shares Outstanding |